Semaglutide: a game changer for metabolic diseases?

Semaglutide: a game changer for metabolic diseases?

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) molecule approved for the treatment of both type 2 diabetes (T2D) and obesity. Semaglutide has a greater impact on glycated haemoglobin (HbA1c) reduction, compared to other GLP-1 RAs, and is the first molecule of this class availab...

Full description

Bibliographic Details
Main Authors:	Agostino Milluzzo, Lucia Manuella, Laura Sciacca
Format:	Article
Language:	English
Published:	Open Exploration Publishing Inc. 2022-04-01
Series:	Exploration of Medicine
Subjects:	glucagon-like peptide 1 receptor agonists type 2 diabetes obesity major adverse cardiovascular events renal disease non-alcoholic steatohepatitis non-alcoholic fatty liver disease diabetes retinopathy
Online Access:	https://www.explorationpub.com/Journals/em/Article/100183

Similar Items

Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study
by: Kai-Cheng Chang, et al.
Published: (2024-10-01)

The benefits of GLP1 receptors in cardiovascular diseases
by: Lamija Ferhatbegović, et al.
Published: (2023-12-01)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
by: L. Kořínková, et al.
Published: (2020-11-01)

Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
by: Kanokwan Pinyopornpanish, et al.
Published: (2021-11-01)

Preventing NASH with Empagliflozin and Linagliptin: A Diabetic Drug Combination
by: Asma Abdul Razzak, et al.
Published: (2023-10-01)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
by: Peter Rossing, et al.
Published: (2023-08-01)

Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
by: Francesco Natale, et al.
Published: (2024-05-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
by: Jinmi Lee, et al.
Published: (2012-08-01)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
by: Xue H, et al.
Published: (2023-05-01)

Liver Injury and Cell Survival in Non-Alcoholic Steatohepatitis Regulated by Sex-Based Difference through B Cell Lymphoma 6
by: Akihide Kamiya, et al.
Published: (2022-11-01)

Revolutionizing cardiometabolic health: the dual power of GLP-1 receptor agonists and SGLT2 inhibitors: a review article
by: G. Tomova-Lyutakova, et al.
Published: (2024-12-01)

SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
by: Rong Xu, et al.
Published: (2023-07-01)

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Hayeon Kim, et al.
Published: (2024-10-01)

Ceramides: Nutrient Signals that Drive Hepatosteatosis
by: Scott A. Summers
Published: (2020-01-01)

Acute steatohepatitis, due to extreme metabolic dysregulation, as the first presentation of non-alcoholic fatty liver disease
by: Georgios Kranidiotis, et al.
Published: (2013-05-01)

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Published: (2012-04-01)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
by: Daryl Ramai, et al.
Published: (2021-12-01)

Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease
by: Alexey A. Goncharov, et al.
Published: (2023-10-01)

Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatitis via regulating iron metabolism
by: Xia Ziqiang, et al.
Published: (2023-01-01)

Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients
by: Li-Chun Lin, et al.
Published: (2025-02-01)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
by: Singh Deepak, et al.
Published: (2010-07-01)

Semaglutide and kidney function: friends or enemies?
by: Federica Giofrè, et al.
Published: (2024-02-01)

Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2023-04-01)

Non-alcoholic fatty liver disease and diabetic retinopathy: Is there an association?
by: Mathew Jacob, et al.
Published: (2023-09-01)

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
by: Julia A. Golubeva, et al.
Published: (2023-09-01)

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
by: Seul Ki Han, et al.
Published: (2023-07-01)

Non-alcoholic fatty liver disease: Definition and subtypes
by: Seul Ki Han, et al.
Published: (2023-02-01)

Non-Invasive Serum Markers of Non-Alcoholic Fatty Liver Disease Fibrosis: Potential Tools for Detecting Patients with Cardiovascular Disease
by: Ling-Zi Chen, et al.
Published: (2024-09-01)

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
by: Ju Hyun Shim
Published: (2020-04-01)

Trends and insights in non-alcoholic fatty liver disease (NAFLD) and cognition research
by: Anam Rehman Rehman, et al.
Published: (2025-03-01)

Body Composition and Progression of Biopsy‐Proven Non‐Alcoholic Fatty Liver Disease in Patients With Obesity
by: Qianyi Wan, et al.
Published: (2024-12-01)

Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
by: Bitgyeol Kim, et al.
Published: (2024-09-01)

Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
by: Takao Miwa, et al.
Published: (2024-06-01)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
by: Cristina Piras, et al.
Published: (2021-10-01)

Relationship between serum 25-hydroxyvitamine D and non-alcoholic fatty liver disease
by: S.M. Tkach, et al.
Published: (2023-05-01)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease
by: Gi-Ae Kim, et al.
Published: (2023-04-01)

RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
by: Lourianne Nascimento CAVALCANTE, et al.
Published: (2022-11-01)

Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
by: Jia-Lan Wang, et al.
Published: (2024-03-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
by: Xi Tan, et al.
Published: (2023-11-01)